ALXN-2030

N/A

Report date: 2026/04/06 20:01:48

Base Information

Drug NameALXN-2030
Drug Alias NameALXN-2030
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAlexion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlexion Pharmaceuticals IncAstraZeneca global R & D (China) Co Ltd
Inactive CompaniesN/A
Active IndicationsRejection of organ transplantationRejection of renal transplantation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A